Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Publication ,  Journal Article
Naylor, JC; Kilts, JD; Hulette, CM; Steffens, DC; Blazer, DG; Ervin, JF; Strauss, JL; Allen, TB; Massing, MW; Payne, VM; Youssef, NA; Marx, CE ...
Published in: Biochim Biophys Acta
August 2010

The neurosteroid allopregnanolone has pronounced neuroprotective actions, increases myelination, and enhances neurogenesis. Evidence suggests that allopregnanolone dysregulation may play a role in the pathophysiology of Alzheimer's disease (AD) and other neurodegenerative disorders. Our prior data demonstrate that allopregnanolone is reduced in prefrontal cortex in male patients with AD compared to male cognitively intact control subjects, and inversely correlated with neuropathological disease stage (Braak and Braak). We therefore determined if allopregnanolone levels are also reduced in AD patients compared to control subjects in temporal cortex, utilizing a larger set of samples from both male and female patients. In addition, we investigated if neurosteroids are altered in subjects who are APOE4 allele carriers. Allopregnanolone, dehydroepiandrosterone (DHEA), and pregnenolone levels were determined in temporal cortex postmortem samples by gas chromatography/mass spectrometry, preceded by high performance liquid chromatography (40 subjects with AD/41 cognitively intact control subjects). Allopregnanolone levels are reduced in temporal cortex in patients with AD (median 2.68 ng/g, n=40) compared to control subjects (median 5.64 ng/g, n=41), Mann-Whitney p=0.0002, and inversely correlated with Braak and Braak neuropathological disease stage (Spearman r=-0.38, p=0.0004). DHEA and pregnenolone are increased in patients with AD compared to control subjects. Patients carrying an APOE4 allele demonstrate reduced allopregnanolone levels in temporal cortex (Mann-Whitney p=0.04). In summary, our findings indicate that neurosteroids are altered in temporal cortex in patients with AD and related to neuropathological disease stage. In addition, the APOE4 allele is associated with reduced allopregnanolone levels. Neurosteroids may be relevant to the neurobiology and therapeutics of AD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biochim Biophys Acta

DOI

ISSN

0006-3002

Publication Date

August 2010

Volume

1801

Issue

8

Start / End Page

951 / 959

Location

Netherlands

Related Subject Headings

  • Temporal Lobe
  • Pregnanolone
  • Postmortem Changes
  • Models, Biological
  • Middle Aged
  • Male
  • Humans
  • Gas Chromatography-Mass Spectrometry
  • Female
  • Cognition
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Naylor, J. C., Kilts, J. D., Hulette, C. M., Steffens, D. C., Blazer, D. G., Ervin, J. F., … Marx, C. E. (2010). Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta, 1801(8), 951–959. https://doi.org/10.1016/j.bbalip.2010.05.006
Naylor, Jennifer C., Jason D. Kilts, Christine M. Hulette, David C. Steffens, Dan G. Blazer, John F. Ervin, Jennifer L. Strauss, et al. “Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.Biochim Biophys Acta 1801, no. 8 (August 2010): 951–59. https://doi.org/10.1016/j.bbalip.2010.05.006.
Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, Ervin JF, et al. Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta. 2010 Aug;1801(8):951–9.
Naylor, Jennifer C., et al. “Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.Biochim Biophys Acta, vol. 1801, no. 8, Aug. 2010, pp. 951–59. Pubmed, doi:10.1016/j.bbalip.2010.05.006.
Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, Ervin JF, Strauss JL, Allen TB, Massing MW, Payne VM, Youssef NA, Shampine LJ, Marx CE. Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta. 2010 Aug;1801(8):951–959.

Published In

Biochim Biophys Acta

DOI

ISSN

0006-3002

Publication Date

August 2010

Volume

1801

Issue

8

Start / End Page

951 / 959

Location

Netherlands

Related Subject Headings

  • Temporal Lobe
  • Pregnanolone
  • Postmortem Changes
  • Models, Biological
  • Middle Aged
  • Male
  • Humans
  • Gas Chromatography-Mass Spectrometry
  • Female
  • Cognition